# MSH2

## Overview
MSH2 is a gene located on chromosome 2 in humans that encodes the protein MutS homolog 2, a key component of the DNA mismatch repair (MMR) system. This protein plays a crucial role in maintaining genomic stability by recognizing and initiating the repair of base mismatches and insertion/deletion loops that occur during DNA replication and recombination. MutS homolog 2 forms heterodimers with MSH6 or MSH3 to create the MutSÎ± and MutSÎ² complexes, respectively, which are essential for the repair of different types of DNA mismatches. The protein's involvement extends beyond mismatch repair, as it also interacts with other cellular pathways, including cell cycle control and apoptosis, highlighting its multifunctional role in protecting the cell from genetic anomalies (Bellacosa2001Functional; Seifert2006The).

## Structure
The MSH2 protein, encoded by the MSH2 gene, is a crucial component of the DNA mismatch repair system, forming heterodimers primarily with MSH6 or MSH3. Structurally, MSH2 is part of the MutSÎ± complex and exhibits a complex architecture divided into several domains, each playing a specific role in its function.

The protein consists of five main domains: the mismatch binding domain, the connector domain, the lever domain, the clamp domain, and the ATPase domain. The mismatch binding domain is responsible for the initial recognition of DNA mismatches. This domain, along with the clamp domain, facilitates the interaction with DNA, enhancing the stability of the protein-DNA complex (Edelbrock2013Structural; Mukherjee2009Deciphering). The ATPase domain is highly conserved and shares a bilobed mixed alpha-beta structure typical of ABC transporters, crucial for the ATP hydrolysis necessary for mismatch repair processes (Warren2007Structure).

MSH2's structure is described as an asymmetric oval disc in the MutSa heterodimer, with the ATPase domains located at one end of the oval, far from the DNA binding sites. This arrangement suggests a sophisticated mechanism of action where ATP binding and hydrolysis induce conformational changes essential for the DNA repair process (Edelbrock2013Structural; Warren2007Structure).

Overall, the structural details of MSH2 highlight its critical role in maintaining genomic integrity through the DNA mismatch repair pathway.

## Function
MSH2, a crucial component of the DNA mismatch repair (MMR) system, plays a vital role in maintaining genomic stability by correcting base mismatches and insertion/deletion loops that occur during DNA replication and recombination. This gene encodes a protein that forms heterodimers with MSH6 or MSH3, known as MutSÎ± and MutSÎ², respectively. MutSÎ± primarily recognizes and binds to base-base mismatches and 1-bp insertion/deletion loops, while MutSÎ² is responsible for repairing larger loops up to 12-bp in length (Bellacosa2001Functional; Ollila2008Mechanisms).

MSH2 is also involved in the cell cycle control and apoptosis, particularly in response to DNA damage. It interacts with other proteins involved in the DNA damage response, such as CHK1 and CHK2, to activate cell cycle checkpoints and prevent the progression of the cell cycle in the presence of DNA damage. This interaction is crucial for the activation of the G2/M checkpoint, which prevents cells from entering mitosis with damaged DNA (Seifert2006The).

Furthermore, MSH2 interacts with nucleotide excision repair pathways, including transcription-coupled repair (TCR) and global genome repair (GGR), to recognize and initiate the repair of specific DNA lesions such as cisplatin adducts and 8-oxoguanine mismatches (Bellacosa2001Functional). This multifaceted involvement in different DNA repair pathways underscores its essential role in protecting cells from both environmental and endogenous DNA damage, thereby contributing to the prevention of diseases like cancer.

## Clinical Significance
Mutations in the MSH2 gene are primarily associated with Lynch syndrome (LS), a hereditary condition that significantly increases the risk of developing colorectal cancer and other malignancies such as endometrial, ovarian, gastric, and urinary tract cancers. Individuals with MSH2 mutations exhibit a higher risk of developing these cancers compared to mutations in other mismatch repair genes like MLH1 (Ramsoekh2009Cancer; Vasen2001MSH2). The lifetime risk of colorectal cancer in MSH2 mutation carriers can be particularly high, with significant implications for cancer screening and management (Stockman2013Cancer).

MSH2 mutations are also linked to Muir-Torre syndrome (MTS), a variant of Lynch syndrome characterized by the presence of sebaceous tumors and keratoacanthomas. This association underscores the broader spectrum of cancer risks associated with MSH2 mutations, including rare tumors like sarcomas (de2020Clinical). The presence of MSH2 mutations has been observed in sarcomas, where these mutations contribute to high microsatellite instability and loss of heterozygosity, further implicating MSH2 in a range of tumorigenic processes (de2020Clinical).

Surveillance and management strategies for individuals with MSH2 mutations are critical, given the broad spectrum of associated cancers and the high risk of malignancy. This necessitates a comprehensive approach to monitoring and intervention to manage the increased cancer risk effectively.

## Interactions
MSH2, a key protein in DNA mismatch repair, forms stable complexes with other proteins such as MSH6 and MSH3, creating MutSÎ± and MutSÎ² respectively, which are crucial for recognizing and initiating repair of specific DNA mismatches (Edelbrock2013Structural; Gradia1997The). These complexes interact with mismatched DNA and nucleotides, where MSH2's role is enhanced by ATP binding and hydrolysis, influencing its interaction with DNA (Antony2003Mismatch; Gradia1997The). MSH2 also interacts with ERCC1 and XPF proteins, suggesting its involvement in other repair pathways beyond mismatch repair (Lan2004Functional). Additionally, MSH2 interacts with OTUB1, where the interaction is mediated by the middle C1 domain of OTUB1, indicating a role in protein stability and possibly ubiquitination processes (Wu2021OTUB1). The interaction with Exo1, particularly through the SHIP1 and SHIP2 sites within Exo1, highlights MSH2's role in the excision step of mismatch repair (Goellner2018Identification). These interactions underline the multifunctional role of MSH2 in maintaining genomic stability through various protein complexes and pathways.


## References


[1. (Bellacosa2001Functional) A Bellacosa. Functional interactions and signaling properties of mammalian dna mismatch repair proteins. Cell Death &amp; Differentiation, 8(11):1076â1092, October 2001. URL: http://dx.doi.org/10.1038/sj.cdd.4400948, doi:10.1038/sj.cdd.4400948. (143 citations) 10.1038/sj.cdd.4400948](https://doi.org/10.1038/sj.cdd.4400948)

[2. (Seifert2006The) Markus Seifert and JÃ¶rg Reichrath. The role of the human dna mismatch repair gene hmsh2 in dna repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. Journal of Molecular Histology, 37(5â7):301â307, November 2006. URL: http://dx.doi.org/10.1007/s10735-006-9062-5, doi:10.1007/s10735-006-9062-5. (88 citations) 10.1007/s10735-006-9062-5](https://doi.org/10.1007/s10735-006-9062-5)

[3. (Stockman2013Cancer) J.A. Stockman. Cancer risks associated with germline mutations in mlh1, msh2, and msh6 genes in lynch syndrome. Yearbook of Pediatrics, 2013:518â520, January 2013. URL: http://dx.doi.org/10.1016/j.yped.2011.10.021, doi:10.1016/j.yped.2011.10.021. (1287 citations) 10.1016/j.yped.2011.10.021](https://doi.org/10.1016/j.yped.2011.10.021)

[4. (Wu2021OTUB1) Qiong Wu, Yaping Huang, Liya Gu, Zhijie Chang, and Guo-Min Li. Otub1 stabilizes mismatch repair protein msh2 by blocking ubiquitination. Journal of Biological Chemistry, 296:100466, January 2021. URL: http://dx.doi.org/10.1016/j.jbc.2021.100466, doi:10.1016/j.jbc.2021.100466. (15 citations) 10.1016/j.jbc.2021.100466](https://doi.org/10.1016/j.jbc.2021.100466)

[5. (Edelbrock2013Structural) Michael A. Edelbrock, Saravanan Kaliyaperumal, and Kandace J. Williams. Structural, molecular and cellular functions of msh2 and msh6 during dna mismatch repair, damage signaling and other noncanonical activities. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 743â744:53â66, March 2013. URL: http://dx.doi.org/10.1016/j.mrfmmm.2012.12.008, doi:10.1016/j.mrfmmm.2012.12.008. (147 citations) 10.1016/j.mrfmmm.2012.12.008](https://doi.org/10.1016/j.mrfmmm.2012.12.008)

[6. (Antony2003Mismatch) Edwin Antony and Manju M. Hingorani. Mismatch recognition-coupled stabilization of msh2-msh6 in an atp-bound state at the initiation of dna repair. Biochemistry, 42(25):7682â7693, June 2003. URL: http://dx.doi.org/10.1021/bi034602h, doi:10.1021/bi034602h. (81 citations) 10.1021/bi034602h](https://doi.org/10.1021/bi034602h)

[7. (Mukherjee2009Deciphering) Shayantani Mukherjee, Sean M. Law, and Michael Feig. Deciphering the mismatch recognition cycle in muts and msh2-msh6 using normal-mode analysis. Biophysical Journal, 96(5):1707â1720, March 2009. URL: http://dx.doi.org/10.1016/j.bpj.2008.10.071, doi:10.1016/j.bpj.2008.10.071. (37 citations) 10.1016/j.bpj.2008.10.071](https://doi.org/10.1016/j.bpj.2008.10.071)

[8. (Warren2007Structure) Joshua J. Warren, Timothy J. Pohlhaus, Anita Changela, Ravi R. Iyer, Paul L. Modrich, and Lorena S. Beese. Structure of the human mutsÎ± dna lesion recognition complex. Molecular Cell, 26(4):579â592, May 2007. URL: http://dx.doi.org/10.1016/j.molcel.2007.04.018, doi:10.1016/j.molcel.2007.04.018. (283 citations) 10.1016/j.molcel.2007.04.018](https://doi.org/10.1016/j.molcel.2007.04.018)

[9. (Lan2004Functional) Li Lan, Tsuyuko Hayashi, Rokshana M. Rabeya, Satoshi Nakajima, Shin-ichiro Kanno, Masashi Takao, Tsukasa Matsunaga, Masafumi Yoshino, Minoru Ichikawa, Hein te Riele, Shigeru Tsuchiya, Kiyoji Tanaka, and Akira Yasui. Functional and physical interactions between ercc1 and msh2 complexes for resistance to cis-diamminedichloroplatinum(ii) in mammalian cells. DNA Repair, 3(2):135â143, February 2004. URL: http://dx.doi.org/10.1016/j.dnarep.2003.10.005, doi:10.1016/j.dnarep.2003.10.005. (84 citations) 10.1016/j.dnarep.2003.10.005](https://doi.org/10.1016/j.dnarep.2003.10.005)

[10. (Vasen2001MSH2) H. F.A. Vasen, A. Stormorken, F. H. Menko, F. M. Nagengast, J. H. Kleibeuker, G. Griffioen, B. G. Taal, P. Moller, and J. T. Wijnen. Msh2 mutation carriers are at higher risk of cancer than mlh1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. Journal of Clinical Oncology, 19(20):4074â4080, October 2001. URL: http://dx.doi.org/10.1200/jco.2001.19.20.4074, doi:10.1200/jco.2001.19.20.4074. (283 citations) 10.1200/jco.2001.19.20.4074](https://doi.org/10.1200/jco.2001.19.20.4074)

[11. (Ramsoekh2009Cancer) Dewkoemar Ramsoekh, Anja Wagner, Monique E van Leerdam, Dennis Dooijes, Carli MJ Tops, Ewout W Steyerberg, and Ernst J Kuipers. Cancer risk in mlh1, msh2 and msh6 mutation carriers; different risk profiles may influence clinical management. Hereditary Cancer in Clinical Practice, December 2009. URL: http://dx.doi.org/10.1186/1897-4287-7-17, doi:10.1186/1897-4287-7-17. (87 citations) 10.1186/1897-4287-7-17](https://doi.org/10.1186/1897-4287-7-17)

[12. (Ollila2008Mechanisms) Saara Ollila, Denis Dermadi Bebek, Josef Jiricny, and Minna NystrÃ¶m. Mechanisms of pathogenicity in humanmsh2missense mutants. Human Mutation, 29(11):1355â1363, November 2008. URL: http://dx.doi.org/10.1002/humu.20893, doi:10.1002/humu.20893. (77 citations) 10.1002/humu.20893](https://doi.org/10.1002/humu.20893)

[13. (de2020Clinical) NathÃ¡lia de Angelis de Carvalho, Bianca Naomi Niitsuma, Vanessa Nascimento Kozak, Felipe Dâalmeida Costa, Mariana Petaccia de Macedo, Bruna Elisa Catin Kupper, Maria LetÃ­cia Gobo Silva, Maria Nirvana Formiga, Sahlua Miguel Volc, Samuel Aguiar Junior, Edenir Inez Palmero, JosÃ© ClÃ¡udio Casali-da-Rocha, Dirce Maria Carraro, and Giovana Tardin Torrezan. Clinical and molecular assessment of patients with lynch syndrome and sarcomas underpinning the association with msh2 germline pathogenic variants. Cancers, 12(7):1848, July 2020. URL: http://dx.doi.org/10.3390/cancers12071848, doi:10.3390/cancers12071848. (14 citations) 10.3390/cancers12071848](https://doi.org/10.3390/cancers12071848)

[14. (Goellner2018Identification) Eva M. Goellner, Christopher D. Putnam, William J. Graham, Christine M. Rahal, Bin-Zhong Li, and Richard D. Kolodner. Identification of exo1-msh2 interaction motifs in dna mismatch repair and new msh2-binding partners. Nature Structural &amp; Molecular Biology, 25(8):650â659, July 2018. URL: http://dx.doi.org/10.1038/s41594-018-0092-y, doi:10.1038/s41594-018-0092-y. (48 citations) 10.1038/s41594-018-0092-y](https://doi.org/10.1038/s41594-018-0092-y)

[15. (Gradia1997The) Scott Gradia, Samir Acharya, and Richard Fishel. The human mismatch recognition complex hmsh2-hmsh6 functions as a novel molecular switch. Cell, 91(7):995â1005, December 1997. URL: http://dx.doi.org/10.1016/s0092-8674(00)80490-0, doi:10.1016/s0092-8674(00)80490-0. (265 citations) 10.1016/s0092-8674(00)80490-0](https://doi.org/10.1016/s0092-8674(00)80490-0)